Successful treatment of tuberculosis (TB) can be hampered by Mycobacterium tuberculosis
populations that are temporarily able to survive antibiotic pressure in the absence of drug …

Abstract Treatment of tuberculosis (TB) has been a therapeutic challenge because of not
only the naturally high resistance level of Mycobacterium tuberculosis to antibiotics but also …

Tuberculosis is the leading infectious cause of death worldwide, with 9· 6 million cases and
1· 5 million deaths reported in 2014. WHO estimates 480 000 cases of these were multidrug …

Certain infectious diseases caused by pathogenic bacteria are typically chronic in nature.
Potentially deadly examples include tuberculosis, caused by Mycobacterium tuberculosis …

The success of Mycobacterium tuberculosis as a pathogen is largely attributable to its ability
to persist in host tissues, where drugs that are rapidly bactericidal in vitro require prolonged …

Successful treatment of human tuberculosis requires 6–9 months' therapy with multiple
antibiotics. Incomplete clearance of tubercle bacilli frequently results in disease relapse …

Background Resistance to antibiotics is a major public-health problem, and studies that link
antibiotic use and resistance have shown an association but not a causal effect. We used …

Mycobacterial persisters, the survivors from antibiotic exposure, necessitate the lengthy
treatment of tuberculosis (TB) and pose a significant challenge for our control of the disease …

Tuberculosis (TB) has become a curable disease, thanks to the discovery of antibiotics.
However, it has remained one of the most difficult infections to treat. Most current TB …

While the DNA sequence is largely responsible for transmitting phenotypic traits over
evolutionary time, organisms are also considerably affected by phenotypic variations that …